04:38 PM EDT, 03/21/2024 (MT Newswires) -- Nkarta ( NKTX ) late Thursday reported a Q4 net loss of $0.57 per diluted share, compared with a $0.67 loss a year earlier.

Analysts polled by Capital IQ expected $0.60.

As expected, the company had no revenue during the three months ended Dec. 31.

The cell therapies company had cash, cash equivalents, and investments on hand of $250.9 million at the end of 2023, which it expects will fund its current operating plan into 2026.

Nkarta ( NKTX ) shares were nearly 2% higher in extended Thursday activity.

Price: 13.23, Change: +0.25, Percent Change: +1.93